Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Restoring Insulin Secretion Adult Medication Study
Brief Summary: The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Adult participants (ages 20-65) will be randomized to one of the following treatment regimens: (1) blinded placebo, (2) blinded metformin alone, (3) early intensive insulin treatment with basal insulin glargine followed by open-label metformin, (4) the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide plus open-label metformin.

The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.


Options:
A: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Arm Label: LY2189265 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: LY2189265 0.75 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Metformin, Drug: Glimepiride | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin

Answer: A